Correction to: CART cells are prone to Fas- and DR5-mediated cell death

Benjamin O Tschumi¹, Nina Dumauthioz¹, Bastien Marti¹, Lianjun Zhang¹, Evripidis Lanitis^{2

3}, Melita Irving^{2

3}, Pascal Schneider⁴, Jean-Pierre Mach⁴, George Coukos^{2

3}, Pedro Romero¹, Alena Donda⁵

Affiliations

¹ Department of Fundamental Oncology, Translational Tumor Immunology Group, Lausanne, Switzerland.
² Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
³ Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.
⁴ Department of Biochemistry, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
⁵ Department of Fundamental Oncology, Translational Tumor Immunology Group, Lausanne, Switzerland. Alena.donda@unil.ch.

Published Erratum

Benjamin O Tschumi et al. J Immunother Cancer. 2018.

. 2018 Sep 25;6(1):92.

doi: 10.1186/s40425-018-0410-2.

¹ Department of Fundamental Oncology, Translational Tumor Immunology Group, Lausanne, Switzerland.
² Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
³ Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.
⁴ Department of Biochemistry, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
⁵ Department of Fundamental Oncology, Translational Tumor Immunology Group, Lausanne, Switzerland. Alena.donda@unil.ch.

Abstract

After publication of this article [1], it was noticed that 3 authors were missed from the author list.

All co-authors declare that they have no competing interests.

CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A. Tschumi BO, et al. J Immunother Cancer. 2018 Jul 13;6(1):71. doi: 10.1186/s40425-018-0385-z. J Immunother Cancer. 2018. PMID: 30005714 Free PMC article.

1. Tschumi BO, Dumauthioz N, Marti B, Zhang L, Schneider P, Mach J-P, et al. CART cells are prone to Fas- and DR5-mediated cell death. J Immuno Cancer. 2018;6:71. doi: 10.1186/s40425-018-0385-z. - DOI - PMC - PubMed